News
-
Physical Properties Scientist, GlaxoSmithKline, Ware, Hertfordshire Basic qualifications: Extensive experience in pharmaceutical development, and physical property characterisation. A good knowledge of analytical techniques relating to solid state and powder properties and the ability to work… Read more . . .
-
Verona Pharma has successfully completed a Phase 2 study of the duration of bronchodilator action by its lead drug RPL554 in patients with mild asthma, according to the company. RPL554 is a novel long-acting phosphodiesterase… Read more . . .
-
After the FDA’s acceptance of Alexza Pharmaceuticals’s resubmitted NDA for Adasuve, the company has announced that the Prescription Drug User Fee Act (PDUFA) goal date will be February 4, 2012. Alexza had received a complete… Read more . . .
-
The FDA has approved a pre-market approval (PMA) application from Intersect ENT for its Propel mometasone furoate drug delivery implant for the treatment of chronic sinusitis. The dissolvable device is inserted in the sinus cavity… Read more . . .
-
Aegis Therapeutics has received US Patent No. 7,998,927 for stabilized formulations of GLP-1 peptide analogs that can be delivered by a variety of different routes, including intranasal. All currently available GLP-1 formulations, which can control… Read more . . .
-
NexBio, which was recently raided by the US Federal Bureau of Investigation (FBI), has announced results from a Phase 2 clinical trial of its Fludase inhaled antiviral for the treatment of influenza. According to the… Read more . . .
-
Massacheusetts biotech company Pulmatrix has secured $14 million in additional funding from its existing investors, including Polaris Venture Partners, 5AM Ventures, Arch Venture Partners, and Novartis Venture Fund, bringing its total to $60 million. Terry… Read more . . .
-
The United States Patent and Trademark Office (USPTO) has issued US Patent No. 7,994,197, titled “Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile,” to MAP Pharmaceuticals for its… Read more . . .
-
A leading pharmaceutical company has an exciting opportunity for an experienced device engineer. This position is based in Switzerland. In this role you will: • Support and lead inhalation device development projects • Mentor fellow… Read more . . .
-
After a meeting with the FDA, MannKind Corporation has announced that the company and the agency have confirmed protocols for new efficacy and safety studies of Afrezza inhaled insulin. The original studies of Afrezza were… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK


